Impact of 18F-FDG-PET/CT on the identification of regional lymph node metastases and delineation of the primary tumor in esophageal squamous cell carcinoma patients.
Stefan MünchLisa MarrBenedikt FeuereckerHendrik DapperRickmer BrarenStephanie E CombsMarciana-Nona DumaPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2020)
Significantly more LNM were identified with 18F‑FDG-PET/CT (177 LNM) compared to CT alone (131 LNM, p < 0.001). The most common sites of LNM were paraesophageal (63% of patients, 37% of LNM) and paratracheal (33% of patients, 20% of LNM), while less than 5% of patients had supraclavicular, subaortic, diaphragmatic, or hilar LNM. With regard to the primary tumor, 51% of LNM were at the same height, while 25% and 24% of lymph node metastases were above and below the primary tumor, respectively. For thirty-three LNM (19%), the distance to the primary tumor was larger than 4 cm. No significant difference was seen between LCT/EUS (median 6 cm) and LPET (median 6 cm, p = 0.846) CONCLUSION: 18F‑FDG-PET can help to identify subclinical lymph node metastases which are located outside of recommended radiation fields. PET-based involved-field irradiation might be the ideal compromise between small treatment volumes and decreasing the risk of undertreatment of subclinical metastatic lymph nodes and should be further evaluated.
Keyphrases
- lymph node
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- small cell lung cancer
- magnetic resonance imaging
- positron emission tomography
- neoadjuvant chemotherapy
- magnetic resonance
- body mass index
- patient reported outcomes
- radiation therapy
- radiation induced
- patient reported
- smoking cessation